Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein
Resumen: Polo like kinase 2 (PLK2), a serine/threonine serum inducible kinase, has been proposed to be the major factor responsible for phosphorylating alpha-synuclein (a-syn) at Serine-129 (Ser-129) in Parkinson''s disease (PD). A suitable strategy to gain insights into PLK2’s biological effects might be to increase PLK2 intracellular levels with the aim of reproducing the slow progressive neuronal changes that occur in PD. The goal of this study was to develop and characterize a novel drug delivery system (DDS) for PLK2 cytosolic delivery using Total recirculating one machine system (TROMS), a technique capable of encapsulating fragile molecules while maintaining their native properties. A protocol for nanoparticle (NP) preparation using TROMS was set up. NPs showed a mean diameter of 257 ± 15.61 nm and zeta potential of -16 ± 2 mV, suitable for cell internalization. TEM and SEM images showed individual, spherical, dispersed NPs. The drug entrapment efficacy was 61.86 ± 3.9%. PLK2-NPs were able to enter SH-SY5Y cells and phosphorylate a-syn at Ser-129, demonstrating that the enzyme retained its activity after the NP manufacturing process. This is the first study to develop a DDS for continuous intracellular delivery of PLK2. These promising results indicate that this novel nanotechnology approach could be used to elucidate the biological effects of PLK2 on dopaminergic neurons.
Idioma: Inglés
DOI: 10.1016/j.ijpharm.2016.06.044
Año: 2016
Publicado en: International Journal of Pharmaceutics 514, 1 (2016), 142-149
ISSN: 0378-5173

Factor impacto JCR: 3.649 (2016)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 56 / 256 = 0.219 (2016) - Q1 - T1
Factor impacto SCIMAGO: 1.323 - Pharmaceutical Science (Q1)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI12-01730
Tipo y forma: Article (PostPrint)
Área (Departamento): Área Ingeniería Química (Dpto. Ing.Quím.Tecnol.Med.Amb.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.


Exportado de SIDERAL (2020-02-21-13:16:44)

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2018-05-22, last modified 2020-02-21


Postprint:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)